Key points are not available for this paper at this time.
As the global population continues to age, the prevalence of Alzheimer's disease (AD) escalates, placing a significant strain on healthcare systems worldwide. While diagnostic methods and therapeutic drugs for AD remain in development, digital therapy emerges as a novel non-pharmacological treatment or adjunctive measure, offering a promising avenue for the diagnosis, prevention, treatment, and management of AD. This article provides an overview of digital therapeutics (DTx) applications, encompassing cognitive assessment, intervention, and risk management, with the intent of informing clinical practice in AD. DTx employs software-driven interventions, such as cognitive training and virtual reality, customized to address patient needs, thereby furnishing real-time assistance to caregivers and patients alike. However, despite its potential, DTx encounters challenges regarding evidence consistency and integration into existing healthcare frameworks. Future research endeavors should prioritize robust experimental designs and interdisciplinary collaborations to enhance the efficacy and accessibility of DTx. Policymakers and healthcare providers must consider the integration and training of DTx to fully harness their benefits in AD management. This study underscores the pivotal role of DTx in shaping the future of AD care and emphasizes the necessity for concerted collaborative efforts across research, policy, and practice domains.
Chenshan Huang (Thu,) studied this question.